Stocks Health care LFCR
NASDAQ · Health careLifecore Biomedical, Inc. DE (LFCR)
Lifecore Biomedical, Inc. DE reported revenue of $128.9M in fiscal 2025, up 0.5% from a year earlier. It posted a net loss of $38.7M. In fiscal 2025 capital spending exceeded operating cash flow by $13.6M. At June 30, 2026 it held $17.2M in cash against $155.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What Lifecore Biomedical, Inc. DE does
Lifecore Biomedical, Inc. DE is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LFCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $128.9M | -$38.7M | -$1.27 | -$13.6M |
| 2024 | $128.3M | $12M | $0.33 | -$18.1M |
| 2023 | $103.3M | -$99.6M | -$3.32 | n/a |
| 2022 | $111.3M | -$116.7M | -$3.97 | -$48.8M |
| 2021 | $100.9M | -$32.3M | -$1.10 | -$2.8M |
| 2020 | $160.1M | -$38.2M | -$1.31 | -$29.3M |
Latest SEC filings
What Lifecore Biomedical, Inc. DE has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- July 2, 2026
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- June 5, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
- May 6, 2026
- April 27, 2026Passive stake changed SCHEDULE 13G/A
Questions about LFCR
What does Lifecore Biomedical, Inc. DE do?
Lifecore Biomedical, Inc. DE is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LFCR.
Is Lifecore Biomedical, Inc. DE profitable?
No. In fiscal 2025 it reported a net loss of $38.7M on revenue of $128.9M.
How much revenue does Lifecore Biomedical, Inc. DE make?
In fiscal 2025 Lifecore Biomedical, Inc. DE reported revenue of $128.9M. That is 0.5% more than a year earlier.
When did Lifecore Biomedical, Inc. DE last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026.
Similar companies
Follow LFCR
Get an email when Lifecore Biomedical, Inc. DE files with the SEC: results, executive changes, material agreements and annual reports.
Follow LFCR: get an email when it filesWhere the numbers come from
Financial figures are the values Lifecore Biomedical, Inc. DE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.